Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673275 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL27100928 | 0.92 | ALDH1A1 (0.48) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL30355396 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23524407 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL30355594 | 0.91 | ALDH1A1 (0.47) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23524084 | 0.91 | ALDH1A1 (0.47) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23524303 | 0.89 | NPC1 (0.45) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23524321 | 0.89 | TSHR (0.48) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL23524411 | 0.89 | S1PR1 (0.58) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 | |
| SCHEMBL30355682 | 0.89 | TSHR (0.48) | SMN1; SMN2RAB9AHSD17B10ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4025211-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | Trevena, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114585360-A | Methods of using the same for the treatment of epilepsy | 特维娜有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3638235-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | Trevena, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-110831593-A | Compounds for modulating S1P1 activity and methods of use thereof | 特维娜有限公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018231745-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | SMN1; SMN2 1320/4885RAB9A 3056/4885HSD17B10 3702/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | SMN1; SMN2 619/4885RAB9A 2056/4885HSD17B10 1746/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | SMN1; SMN2 1320/4885RAB9A 3056/4885HSD17B10 3702/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | SMN1; SMN2 1320/4885RAB9A 3056/4885HSD17B10 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.